Located in Nantes, France, Effimune is a Biotech company specialized in Immune Regulation for applications in transplantation, autoimmunity and cancer immunotherapy. The originality of Effimune’s therapeutic strategy, compared to conventional immunosuppression, is the modification in the balance between effector and regulatory immune cells. The biological drugs Effimune develops aim to restore the natural balance of these cells by targeting the molecular checkpoint. The expertise of the company lies in its ability to identify new therapeutic targets and develop effective biomolecules for the pharmaceutical industry by validating preclinical and clinical phase I / II proofs of concept and guaranteeing the manufacture of pilot and clinical batches. Effimune is a spin-off of the Nantes Institute of Transplantation Urology Nephrology-(ITUN), created in December 2007.
Contact
Faculté de Médecine
1 Rue Gaston Veil 44035 Nantes Cedex
Tel: +33 (0) 2 40 412 834
email: contact@effimune.com
Web: effimune.com
Bernard Vanhove, CEO and Maryvonne Hiance, Chairman of Effimune, an immune regulation biotech, discuss their novel approach to developing immunotherapies, their partnership and commercialization strategies, their perspective on the landscape…
Joël Jaouen, president of France Alzheimer, provides important insights into the role and objectives of the patient association. He explains why France Alzheimer together with other learned societies filed a…
PharmaBoardroom’s list of personalities whose voices, opinions and decisions matter in French pharma’s industry, regulatory affairs, reimbursement and pricing. Maurice-Pierre Planel — President of CEPS Maurice-Pierre Planel Has been…
Lundbeck France and Benelux’s Lourdes Pla discusses Europe-wide restructuring, the importance of the French affiliate to the global group and the government’s attitude towards healthcare and neuroscience. We are…
Gérard Raymond, president of the Fédération Francaise des Diabétiques (FFD – French Diabetes Federation), gives an update on the situation of diabetes in France and explains the challenges for patient…
Christophe Cizeron, president of Lyonbiopole, discusses the important economic and industrial position of the research cluster in the Rhone-Alps Region as well as the challenges posed by domestic and international…
Vincent Leonhardt explains how the French administration’s zeal for life science innovation can actually place pressure on some pharma SMEs. He also discusses the challenges he faced during his first…
Pierre Moustial, CEO of URGO Group, explains the life-changing advancement in wound care treatments that URGO has been providing to patients all over the world as well as his upcoming…
Thomas Courbe, general director of the DGE (Direction Générale des Entreprises – General Directorate for Enterprises), speaks about the role of the DGE and the implementation of new policies oriented…
Stéphane Roques, CEO of Medicen, the health care cluster for the Paris region, discusses his vision for Medicen and the changes he has made during his first few months in…
Pierre Moustial, chairman of MedTech in France, the association of medical technology companies in France, discusses the challenges for French healthcare start-ups to scale-up and explains why France has no…
Frédérique Vidal, the French Minister of Higher Education, Research and Innovation, discusses her plans to create innovation campuses to facilitate the collaboration between industry, institutes and academia. She also highlights…
Cancer is the leading cause of death in France, accounting for 28.5% of all deaths in 2014, followed by cardiovascular diseases, which accounted for 25%. However, there are gender differences:…
See our Cookie Privacy Policy Here
